Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2B Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer

NCT00609622 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00609622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2B Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2008
Completion date
July 31, 2011
Enrollment
191 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.